422 related articles for article (PubMed ID: 22942741)
1. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Kotb MA
Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid for primary biliary cirrhosis.
Gluud C; Christensen E
Cochrane Database Syst Rev; 2002; (1):CD000551. PubMed ID: 11869580
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
Combes B; Emerson SS; Flye NL; Munoz SJ; Luketic VA; Mayo MJ; McCashland TM; Zetterman RK; Peters MG; Di Bisceglie AM; Benner KG; Kowdley KV; Carithers RL; Rosoff L; Garcia-Tsao G; Boyer JL; Boyer TD; Martinez EJ; Bass NM; Lake JR; Barnes DS; Bonacini M; Lindsay KL; Mills AS; Markin RS; Rubin R; West AB; Wheeler DE; Contos MJ; Hofmann AF
Hepatology; 2005 Nov; 42(5):1184-93. PubMed ID: 16250039
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
7. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid for primary biliary cirrhosis.
Gong Y; Huang ZB; Christensen E; Gluud C
Cochrane Database Syst Rev; 2008 Jul; (3):CD000551. PubMed ID: 18677775
[TBL] [Abstract][Full Text] [Related]
9. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
Leuschner M; Maier KP; Schlichting J; Strahl S; Herrmann G; Dahm HH; Ackermann H; Happ J; Leuschner U
Gastroenterology; 1999 Oct; 117(4):918-25. PubMed ID: 10500075
[TBL] [Abstract][Full Text] [Related]
10. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
11. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
[TBL] [Abstract][Full Text] [Related]
14. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
[TBL] [Abstract][Full Text] [Related]
15. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
16. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
Zein CO; Lindor KD
Curr Gastroenterol Rep; 2010 Feb; 12(1):13-22. PubMed ID: 20425480
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid in pregnancy?
de Vries E; Beuers U
J Hepatol; 2019 Dec; 71(6):1237-1245. PubMed ID: 31479696
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
20. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
